- Home
- VRCA vs LVTX Comparison
VRCA vs LVTX Comparison
Compare VRCA & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- LVTX
- Stock Information
- Founded
- VRCA 2013
- LVTX 2016
- Country
- VRCA United States
- LVTX Netherlands
- Employees
- VRCA N/A
- LVTX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- LVTX Health Care
- Exchange
- VRCA Nasdaq
- LVTX Nasdaq
- Market Cap
- VRCA 40.6M
- LVTX 40.0M
- IPO Year
- VRCA 2018
- LVTX 2021
- Fundamental
- Price
- VRCA $3.96
- LVTX $1.48
- Analyst Decision
- VRCA Buy
- LVTX Hold
- Analyst Count
- VRCA 4
- LVTX 4
- Target Price
- VRCA $60.00
- LVTX $1.58
- AVG Volume (30 Days)
- VRCA 348.8K
- LVTX 430.9K
- Earning Date
- VRCA 11-06-2025
- LVTX 12-09-2025
- Dividend Yield
- VRCA N/A
- LVTX N/A
- EPS Growth
- VRCA N/A
- LVTX N/A
- EPS
- VRCA N/A
- LVTX N/A
- Revenue
- VRCA $14,704,000.00
- LVTX $4,990,000.00
- Revenue This Year
- VRCA $332.45
- LVTX N/A
- Revenue Next Year
- VRCA $12.85
- LVTX N/A
- P/E Ratio
- VRCA N/A
- LVTX N/A
- Revenue Growth
- VRCA 5.72
- LVTX N/A
- 52 Week Low
- VRCA $3.82
- LVTX $0.85
- 52 Week High
- VRCA $17.38
- LVTX $2.09
- Technical
- Relative Strength Index (RSI)
- VRCA 39.62
- LVTX 35.44
- Support Level
- VRCA $3.93
- LVTX $1.53
- Resistance Level
- VRCA $4.54
- LVTX $1.59
- Average True Range (ATR)
- VRCA 0.32
- LVTX 0.06
- MACD
- VRCA 0.01
- LVTX -0.01
- Stochastic Oscillator
- VRCA 11.00
- LVTX 15.00
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.